GNOM250117P16000
- 0.00
- 0.000.00%
Global X Fds Genomics & Biotechnology Etf Newsroom
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.
Illumina Announces NovaSeq X Updates With Single-Flow-Cell System, Software Upgrade, New Kits Enhancing Multiomic Capabilities
Wells Fargo Spotlights 31 Names It Believes 'Offer Above-average Growth Potential'
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
Qiagen Analyst Ratings
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Natera Analyst Ratings
Oracle, Snowflake Next up Among Top AI Software Plays in 2025: Wedbush
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
4 Stocks to Watch on Friday: NFLX, AAPL on $4T Watch and More
BioNTech Entered Settlement Agreement With NIH for $791.5M Over COVID-19 Vaccine Royalties (2020-2023)
How Is The Market Feeling About Illumina?
Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years